Targeting genotoxic and proteotoxic stress‐response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram

• Published in: The Prostate Vol. 79; no. 4; pp. 352 - 362
• Main Authors: Majera, Dusana, Skrott, Zdenek, Bouchal, Jan, Bartkova, Jirina, Simkova, Dana, Gachechiladze, Mariam, Steigerova, Jana, Kurfurstova, Daniela, Gursky, Jan, Korinkova, Gabriela, Cwiertka, Karel, Hodny, Zdenek, Mistrik, Martin, Bartek, Jiri
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.03.2019
• Subjects: Alcohol abuse; Apoptosis; Castration; Cell culture; Clinical trials; Copper; Culture media; Cytotoxicity; Disulfiram; DNA damage; DNA repair; Drug abuse; Genotoxicity; Heat shock proteins; Homologous recombination; HSF1 protein; Hsp70 protein; Immunoblotting; Immunofluorescence; Ionizing radiation; Medicin och hälsovetenskap; p53 Protein; PARP; Poly(ADP-ribose) polymerase; Prostate; Prostate cancer; Protein turnover; Proteins; proteotoxic stress; vorinostat; prostate cancer; PARP; disulfiram; vorinostat; proteotoxic stress

Background Castration‐resistant prostate cancer (PCa) represents a serious health challenge. Based on mechanistically‐supported rationale we explored new therapeutic options based on clinically available drugs with anticancer effects, including inhibitors of PARP1 enzyme (PARPi), and histone deacety...